Benign Prostatic Hyperplasia Treatment Therapeutics
1. Avodart patent expiration
Treatment: Method of inhibiting 5 alpha testosterone reductase enzyme with dutasteride or its derivative and treating androgen responsive/mediated disease including benign prostatic hyperplasia; Method of treati...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5998427 | WAYLIS THERAP | Androstenones |
Sep, 2013
(12 years ago) | |
| US5846976 | WAYLIS THERAP | Androstenone derivative |
Sep, 2013
(12 years ago) | |
| US5565467 | WAYLIS THERAP | Androstenone derivative |
Nov, 2015
(10 years ago) | |
Drugs and Companies using DUTASTERIDE ingredient
Market Authorisation Date: 20 November, 2001
Dosage: CAPSULE
How can I launch a generic of AVODART before it's drug patent expiration?
More Information on Dosage
AVODART family patents
2. Uroxatral patent expiration
Treatment: NA
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6149940 | ADVANZ PHARMA | Tablet with controlled release of alfuzosine chlorhydrate |
Aug, 2017
(8 years ago) | |
|
US6149940 (Pediatric) | ADVANZ PHARMA | Tablet with controlled release of alfuzosine chlorhydrate |
Feb, 2018
(7 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-97) | Dec 15, 2013 |
| Pediatric Exclusivity(PED) | Jun 15, 2014 |
Drugs and Companies using ALFUZOSIN HYDROCHLORIDE ingredient
Market Authorisation Date: 12 June, 2003
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of UROXATRAL before it's drug patent expiration?
More Information on Dosage
UROXATRAL family patents